Avelumab (Bavencio)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Avelumab binds to PD-1 and B7.1 receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, avelumab stimulates immune responses, including anti-tumor immune effects.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Toxicity management

Diseases for which it is established (work in progress)

Patient drug information

History of changes in FDA indication

Bladder cancer

Merkel cell carcinoma

Renal cell carcinoma

History of changes in Health Canada indication

  • 2017-12-18: Initial notice of compliance with conditions for the treatment of metastatic Merkel Cell Carcinoma (MCC) in previously treated adults.
    • 2021-01-13: Conditions were met
  • 2018-05-04: Notice of compliance with conditions for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
    • 2019-05-14: Conditions were met
  • 2019-11-06: New indication for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC)
  • 2020-12-10: New indication for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed following first-line platinum-based chemotherapy.

Also known as

  • Code name: MSB0010718C
  • Brand name: Bavencio